Market Overview

GW Pharmaceuticals Shares Jump Following Price Target Raise

Related GWPH
Harvard Explains The Health Effects Of Medical And Recreational Use Of Marijuana
Is GW Pharma's Technical Picture Breaking Down?

In a note released Monday morning, Piper Jaffray made a big raise to the price target of GW Pharmaceuticals (NASDAQ: GWPH) from $97 to $147, citing the potential of GW's Epidiolex to treat epilepsy.

The analysts at Piper Jaffray say that the unique safety/CNS profile make the drug an attractive way to treat epilepsy.

Additionally, the analysts noted that they do not believe INSYS Therapeutics will be able to compete on price.

Following the note, shares of GW Pharmaceuticals are up over six percent in the pre-market.

Latest Ratings for GWPH

Jun 2016Janney CapitalInitiates Coverage onSell
Jun 2016Cantor FitzgeraldInitiates Coverage onBuy
Mar 2016Roth CapitalMaintainsBuy

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color News Price Target Analyst Ratings


Related Articles (GWPH)

View Comments and Join the Discussion!